Navigation Links
ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
Date:1/9/2009

ZURICH, Switzerland, Jan. 9/PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of the Phase I/IIa clinical development of its anti-TNF alpha antibody fragment ESBA105 in osteoarthritis (OA). This double-blind, randomized, placebo-controlled Phase I/IIa clinical study is designed to investigate the safety, tolerability and efficacy on pain with ESBA105 applied locally via intra-articular administration to patients with severely painful OA of the knee. The multicenter study is initiated at various sites across Switzerland.

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, commented, "As of today, no disease-modifying osteoarthritis drug exists, which is the key unmet need. OA is being increasingly recognized as driven by episodes of local inflammation and thus, TNF alpha represents a highly promising target. TNF alpha is excessively generated in OA by chondrocytes, which are located within the cartilage. Thus, to achieve disease-modifying activity, it is expected that the drug needs to penetrate into the cartilage, which cannot be achieved by the currently marketed TNF inhibitors. With ESBA105, we observe a very efficient penetration into the cartilage. By that, inhibiting TNF alpha can address the major aspects of OA therapy: signs and symptoms and cartilage degeneration. If clinically successful, ESBA105 is uniquely positioned to fill the need to treat OA with a safe and effective local therapy. A disease-modifying drug would revolutionize the treatment of this debilitating disease."

TNF alpha is a cytokine and a key player in inflammation, and has been identified as a major contributor to pain (signs and symptoms) and cartilage degeneration (structure modification), the main clinical characteristics of OA. Current treatments for OA comprise mainly of non-steroidal anti-inflammatory drugs and intra-articular injections of hyaluronic acids and cortico
'/>"/>

SOURCE ESBATech AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
2. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
5. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
6. Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
7. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
8. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
9. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
10. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
11. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  The report on breast ... of breast cancer drugs on the basis of the ... originates from the inner lining of milk ducts or ... malignant type of tumor that can spread to other ... which starts in lobules is referred as lobular carcinoma, ...
(Date:9/2/2015)... LONDON , Sept. 2, 2015 ... coil is used to treat an unruptured and ... artery wall). The treatment is either known as ... procedure, the endovascular coil blocks the blood flow ... usually performed under general anaesthesia by an interventional ...
(Date:9/2/2015)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Ron Squarer , will present at the Wells ... is welcome to participate in the conference through ... Fargo Securities Healthcare ConferencePresenter: Ron Squarer, Chief Executive ... a.m. Eastern Time Webcast: www.arraybiopharma.com   ...
Breaking Medicine Technology:Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Neuroendovascular Coil Market 2015-2019 2
... LOS ANGELES, Oct. 24, 2011 NeuroSigma, Inc., a ... has signed a contract with the University of California, ... clinical trial to study the use of non-invasive, external ... Deficit Hyperactivity Disorder (ADHD).  NeuroSigma is the exclusive worldwide ...
... HealthWarehouse.com, Inc. (OTC: HEWA), a leading VIPPS-accredited ... begin providing prescription medications for WhiteGlove Health, Inc., ... excited to have a national partner to provide ... Robert Fabbio, co-founder and chief executive officer of ...
Cached Medicine Technology:NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD 2NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD 3WhiteGlove Health Selects HealthWarehouse.com to Provide Prescription Medications to its Members Nationwide 2
(Date:9/2/2015)... ... September 02, 2015 , ... Alameda County Community Food ... Action Month” during the entire month of September. In the spirit of ... its efforts this September to an awareness campaign educating legislators and the public ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Cancer Center at Children's Healthcare of Atlanta to help support childhood cancer ... discuss the upcoming WSB Radio Care-A-Thon , which is the fund-raising event ...
(Date:9/2/2015)... ... September 02, 2015 , ... Medical ... has completed a recapitalization with new investment partners Beecken Petty O’Keefe & ... each offer extensive expertise and connections within the healthcare industry, which makes ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Every year ... it; others dread it. However, few are prepared to face the academic workload confronting ... starts. Our schools haven’t prepared them since schools don’t teach students how to study. ...
(Date:9/2/2015)... Destin, Florida (PRWEB) , ... September 02, 2015 , ... ... in drug prices over the past year and its negative impact on consumers. It ... regular prescription medication and 10% were paying as much as an extra $100 compared ...
Breaking Medicine News(10 mins):Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2
... says hazard isn,t proven, , SATURDAY, Sept. 5 (HealthDay ... (pronounced THAL ates) are nearly ubiquitous in consumer products, ... plastics and toys. , A little over a decade ... began to focus on phthalates and have been working ...
... , ST. LOUIS, Sept, 4 KV ... Thomas McHugh, the Vice President of Finance and Corporate Controller of ... Mr. McHugh replaces Ronald J. Kanterman, who ceased serving as ... Mr. Kanterman continues to serve as a member of the ...
... NEWPORT BEACH, Calif., Sept. 4 Nationwide Health Properties ... Portfolio Officer, Abdo Khoury, will participate on a healthcare real estate ... Conference on Friday, September 11, 2009 beginning at 7:30 a.m. CDT. ... a live audio-webcast, please us the following link: ...
... University of Toronto have identified a protein which plays ... could enhance our understanding of how the brain works, ... of T graduate student John Calarco, working in the ... and Biomolecular Research, University of Toronto) and Prof. Mei ...
... major episode later, researchers say , FRIDAY, Sept. 4 ... to have major depression, anxiety disorders and eating disorders ... researchers interviewed 755 teenagers who were about age 16 ... substance abuse. , About 8 percent were found to ...
... ... ... American Pharmacists Association (APhA) is recommending that the public begin visiting their ... 80,000 pharmacists have been trained to administer immunizations and have the authority to administer ...
Cached Medicine News:Health News:In Toys and More, Are Chemicals Safe or Harmful? 2Health News:In Toys and More, Are Chemicals Safe or Harmful? 3Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 2Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 3Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 4Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 5Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 6Health News:U of T researchers identify protein 2Health News:Depressed Teens Continue to Suffer 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 3
... System RCS 800 closes various plastic primary and ... way. Different tube heights and diameters can be ... be used for send-outs. The integration into other ... System RSD 800 and High Throughput Sorter RSD ...
... Decapping System DS 800 selectively removes closures from ... the barcode towards the rack opening in one ... integrated in PVT Systems like Sorting System RS ... Sorter RSD ProVolume and Aliquoting System RSD 800A. ...
... Nanogen offers reagents to detect ... human parainfluenza virus 1, 2 and ... and respiratory syncytial virus A and ... reagents to create homebrew tests., ...
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
Medicine Products: